|
Press Releases |
|
|
|
Tuesday, December 6, 2022 |
|
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing |
Leading pharma companies GSK, Sanofi and Takeda will partner with research communities from the Agency for Science, Technology and Research (A*STAR); National University of Singapore (NUS); Nanyang Technological University, Singapore (NTU Singapore) and its innovation and enterprise company, NTUitive; and Singapore Institute of Technology (SIT) to boost Singapore's biologics manufacturing capabilities. more info >> |
|
Thursday, June 2, 2022 |
|
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies |
more info >> |
|
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies |
Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR. more info >> |
|
Thursday, September 30, 2021 |
|
A*STAR and Local SME Work with Vaccination Centres to Deploy AVID System for Filling Syringes |
The Agency for Science, Technology and Research (A*STAR) has developed an Automated Vaccine Inoculation Dispenser (AVID) system, which replaces the manual step of filling injection syringes with vaccine liquid. AVID is customised for the vaccination centres which are set up by the Ministry of Health and operated by private healthcare providers. more info >> |
|
Friday, July 31, 2020 |
|
Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials |
Made-in-Singapore cancer drug, ETC-159, has achieved a new developmental milestone in achieving "First Patient First Visit[1]" in Phase 1B. The first dose of ETC-159 has been administered to patients in this new phase of clinical testing, which for the first time, will look at efficacy in addition to assessing the safety of ETC-159 in treating different types of cancers. more info >> |
|
Friday, July 24, 2020 |
|
MP Biomedicals and A*STAR Co-Develop Rapid Antibody Test Kit for SARS-CoV-2 |
MP Biomedicals Asia Pacific Pte Ltd, a diagnostic corporation which has been operating for over 30 years focusing on various infectious disease testing development and manufacturing, today announced the successful development of a rapid antibody test kit for COVID-19, in collaboration with the Agency for Science, Technology and Research (A*STAR). more info >> |
|
Tuesday, October 22, 2019 |
|
Fujitsu, SMU and A*STAR Launch Digital Platform Experimentation Project using Quantum-Inspired Computing and Deep Learning Technology |
Fujitsu Limited, the Singapore Management University (SMU) and the Agency for Science, Technology and Research (A*STAR)'s Institute of High Performance Computing today announced the launch of the Digital Platform Experimentation Project. more info >> |
|
Fujitsu, SMU and A*STAR Launch Digital Platform Experimentation Project using Quantum-Inspired Computing and Deep Learning Technology |
Fujitsu Limited, the Singapore Management University (SMU) and the Agency for Science, Technology and Research (A*STAR)'s Institute of High Performance Computing today announced the launch of the Digital Platform Experimentation Project. more info >> |
|
Monday, October 21, 2019 |
|
富士通・シンガポール科学技術庁・Singapore Management University、「デジタルアニーラ」とディープラーニング技術を活用したプロジェクトを開始 |
富士通株式会社とシンガポール科学技術庁のハイパフォーマンスコンピューティング研究所(Institute of High Performance Computing)、およびSingapore Management Universityはこのたび、「FUJITSU Quantum-Inspired Computing Digital Annealer」とディープラーニング技術を活用したデジタルプラットフォーム実装プロジェクトを開始します。 more info >> |
|
Friday, June 28, 2019 |
|
Singapore's Drug Development Efforts Given Additional Momentum with National Platforms |
The nation's drug development efforts have been given additional momentum with the introduction of two new platforms, and a grant scheme for drug discovery and development. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
鍋圈:持續擴大業務規模 盈利能力持續增強
Mar 29, 2024 18:07 HKT/SGT
|
|
|
Guoquan: Continuously Expanding the Business Scale While Enhancing Profitability
Mar 29, 2024 18:02 HKT/SGT
|
|
|
直面企业发展转型挑战 联想控股如何发展新质生产力
Mar 29, 2024 17:14 HKT/SGT
|
|
|
直面企業發展轉型挑戰 聯想控股如何發展新質生產力
Mar 29, 2024 17:10 HKT/SGT
|
|
|
联想控股2023年收入4360亿元
Mar 29, 2024 17:05 HKT/SGT
|
|
|
聯想控股2023年收入4360億元
Mar 29, 2024 17:01 HKT/SGT
|
|
|
Legend Holdings Realized Revenue of RMB436 billion in 2023
Mar 29, 2024 16:55 HKT/SGT
|
|
|
Panasonic Energy and Mazda Enter Agreement Towards Supply of Cylindrical Automotive Lithium-ion Batteries
Mar 29, 2024 17:42 JST
|
|
|
Gome Retail Streamlines to Focus on Main Business
Mar 29, 2024 16:07: JST
|
|
|
Gome Fin Tech Announced Annual Results of 2023
Mar 29, 2024 15:36: JST
|
|
|
国美零售瘦身聚焦主业
Mar 29, 2024 15:20 HKT/SGT
|
|
|
國美零售瘦身聚焦主業
Mar 29, 2024 15:15 HKT/SGT
|
|
|
Gome Retail Streamlines to Focus on Main Business
Mar 29, 2024 15:07 HKT/SGT
|
|
|
国美金融科技公布2023年度业绩
Mar 29, 2024 14:53 HKT/SGT
|
|
|
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
Mar 29, 2024 15:51 JST
|
|
|
|
More News >> |
|
|
|
|
|